Abstract
More than 5.5 million people are bitten by venomous snakes every year on a global basis, which leads to an estimated 125,000 deaths and 3 times as many amputations. The cornerstone of snakebite therapy remains to be parental administration of equine or ovine antisera, which are associated with severe side effects due to their heterologous nature. Additionally, cost of antivenom has been identified as one of the key voids hindering snakebite victims from receiving antivenom in sub-Saharan Africa. A widespread notion exists that investing in the development of novel antivenoms based on recombinant expression of human(ized) antibodies or antibody fragments is not commercially attractive. Here, a simple,coarse-grained economical assessment of producing modern antivenoms based on oligoclonal mixtures of humanized antibodies and antibody fragments is presented.
Original language | English |
---|---|
Publication date | 2015 |
Number of pages | 1 |
Publication status | Published - 2015 |
Externally published | Yes |
Event | 18th World Congress of the International Society on Toxinology - The Examination Schools & The Sheldonian Theatre, Oxford, United Kingdom Duration: 25 Sept 2015 → 30 Sept 2015 Conference number: 18 |
Conference
Conference | 18th World Congress of the International Society on Toxinology |
---|---|
Number | 18 |
Location | The Examination Schools & The Sheldonian Theatre |
Country/Territory | United Kingdom |
City | Oxford |
Period | 25/09/2015 → 30/09/2015 |